ORG27569 cannabinoid CB1 receptor allosteric modulator (CAS: 868273-06-7) is a novel compound that acts as an allosteric modulator of the cannabinoid CB1 receptor. It was developed by Organon Pharmaceuticals for the treatment of various neurological and psychiatric disorders, such as anxiety, depression, and addiction.
Chemical name: 3-(3-chlorophenyl)-1-(6-(pyridin-2-yl)pyridin-3-yl)urea
Molecular formula: C20H15ClN4O
Formula weight: 356.82 g/mol
CAS No: 868273-06-7
Top ten keywords from Google:
Synonyms:
Health benefits of this product: ORG27569 has shown potential benefits in preclinical studies for the treatment of various neurological and psychiatric disorders, such as anxiety, depression, and addiction. As an allosteric modulator of the CB1 receptor, it may have distinct advantages over traditional agonists or antagonists, such as fewer side effects and better selectivity.
Potential effects: ORG27569 has demonstrated efficacy in preclinical studies in reducing anxiety-like behaviors, improving depressive symptoms, and reducing drug-seeking behavior in animal models of addiction. It works by modulating the activity of the CB1 receptor in a more selective and subtle manner than traditional agonists or antagonists. Additionally, ORG27569 may have potential benefits for pain management, seizure disorders, and neurodegenerative diseases, although more research is needed in these areas.
Product mechanism: ORG27569 acts as an allosteric modulator of the CB1 receptor, which is a G protein-coupled receptor that plays a key role in the regulation of various physiological processes, such as appetite, pain perception, and mood. Allosteric modulators bind to a different site on the receptor than agonists or antagonists and can either enhance or inhibit its activity depending on the context. In the case of ORG27569, it enhances the activity of the CB1 receptor in a selective and subtle manner.
Safety: The safety profile of ORG27569 has not been extensively studied in humans yet as it is still in the early stages of development. However, preclinical studies have shown that it has a favorable safety profile and does not cause significant adverse effects at therapeutic doses. More research is needed to determine the long-term safety and tolerability of this compound in humans.
Side effects: The potential side effects of ORG27569 are not yet fully known. However, as an allosteric modulator of the CB1 receptor, it may cause some of the same side effects as traditional CB1 agonists or antagonists, such as dizziness, nausea, and changes in appetite or mood. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of ORG27569 have not been established yet, as it is still in the early stages of development. However, preclinical studies have used doses ranging from 0.3 to 30 mg/kg, administered orally or intraperitoneally. The dosing regimen may vary depending on the patient's condition and treatment goals. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: ORG27569 cannabinoid CB1 receptor allosteric modulator (CAS: 868273-06-7) is a novel compound developed by Organon Pharmaceuticals for the treatment of various neurological and psychiatric disorders, such as anxiety, depression, and addiction. Its mechanism of action involves acting as an allosteric modulator of the CB1 receptor in a selective and subtle manner. Although it has shown promise in preclinical studies, more research is needed to determine its full potential and efficacy in humans, as well as its safety profile and dosing regimen
